Edge Therapeutics Inc (EDGE):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Edge Therapeutics Inc (EDGE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8181
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:43
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Edge Therapeutics Inc (Edge Therapeutics) is a clinical-stage biotechnology company that discovers, develops and commercializes hospital-based therapies. The company offers hospital based therapies capable of transforming treatment paradigms in the management of life-threatening, acute neurological conditions. Its lead pipeline products include EG-1962, a proprietary formulation, which is used to treat aneurysmal subarachnoid hemorrhage, is in Phase 3 clinical trials and EG-1964 is in preclinical stage used to prevent recurrent chronic subdural hematoma. The company’s Precise is a proprietary, programmable, biodegradable polymer-based development platform develops products for the treatment of acute neurological conditions. Edge Therapeutics is headquartered in Berkeley Heights, New Jersey, the US.

Edge Therapeutics Inc (EDGE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Edge Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Edge Therapeutics Raises USD56 Million in Series C-2 Financing 10
Edge Therapeutics Raises USD16.5 Million in Series C-1 Financing 12
Edge Therapeutics Raises USD8 Million in Venture Financing 13
Edge Therapeutics Secures USD3 Million from Hercules Technology 14
Edge Therapeutics Raises US$18 Million In Series C Financing 15
Partnerships 16
Edge Therapeutics Amends its Agreement with Oakwood Labs 16
Edge Therapeutics Enters into Research and Discovery Agreement with St. Michael’s Hospital 17
Equity Offering 18
Edge Therapeutics Raises USD18 Million in Private Placement of Shares 18
Edge Therapeutics Raises USD92.5 Million in IPO 20
Edge Therapeutics Raises USD0.15 Million in Private Placement of Preferred Stock 22
Edge Therapeutics Raises USD2.6 Million in Private Placement of Preferred Stock 23
Edge Therapeutics Raises USD3.4 Million in Private Placement of Preferred Stock 24
Edge Therapeutics Raises USD2.5 Million in Private Placement of Preferred Stock 25
Edge Therapeutics Raises USD0.6 Million in Private Placement of Preferred Stock 26
Debt Offering 27
Edge Therapeutics Raises USD0.1 Million in Private Placement of Notes 27
Edge Therapeutics Raises USD0.15 Million in Private Placement of Notes 28
Edge Therapeutics Inc – Key Competitors 29
Edge Therapeutics Inc – Key Employees 30
Edge Therapeutics Inc – Locations And Subsidiaries 31
Head Office 31
Recent Developments 32
Financial Announcements 32
Aug 01, 2018: Edge Therapeutics Reports Second Quarter 2018 Financial Results 32
May 01, 2018: Edge Therapeutics Announces First Quarter 2018 Financial Results 33
Mar 01, 2018: Edge Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results 34
Nov 01, 2017: Edge Therapeutics Reports Third Quarter 2017 Financial Results 35
Aug 01, 2017: Edge Therapeutics Reports Second Quarter 2017 Financial Results and Continued Operational Progress 37
May 03, 2017: Edge Therapeutics Q1 net loss increases 38
May 03, 2017: Edge Therapeutics Reports First Quarter 2017 Financial Results and Continued Operational Progress 39
Mar 02, 2017: Edge Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results 40
Corporate Communications 41
Sep 19, 2017: Edge Therapeutics Appoints Rosemary A. Crane, Pharmaceutical Industry Leader, to its Board of Directors 41
Feb 21, 2017: Edge Therapeutics appoints senior vice president of regulatory affairs 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43

List of Tables
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Edge Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Edge Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Edge Therapeutics Raises USD56 Million in Series C-2 Financing 10
Edge Therapeutics Raises USD16.5 Million in Series C-1 Financing 12
Edge Therapeutics Raises USD8 Million in Venture Financing 13
Edge Therapeutics Secures USD3 Million from Hercules Technology 14
Edge Therapeutics Raises US$18 Million In Series C Financing 15
Edge Therapeutics Amends its Agreement with Oakwood Labs 16
Edge Therapeutics Enters into Research and Discovery Agreement with St. Michael’s Hospital 17
Edge Therapeutics Raises USD18 Million in Private Placement of Shares 18
Edge Therapeutics Raises USD92.5 Million in IPO 20
Edge Therapeutics Raises USD0.15 Million in Private Placement of Preferred Stock 22
Edge Therapeutics Raises USD2.6 Million in Private Placement of Preferred Stock 23
Edge Therapeutics Raises USD3.4 Million in Private Placement of Preferred Stock 24
Edge Therapeutics Raises USD2.5 Million in Private Placement of Preferred Stock 25
Edge Therapeutics Raises USD0.6 Million in Private Placement of Preferred Stock 26
Edge Therapeutics Raises USD0.1 Million in Private Placement of Notes 27
Edge Therapeutics Raises USD0.15 Million in Private Placement of Notes 28
Edge Therapeutics Inc, Key Competitors 29
Edge Therapeutics Inc, Key Employees 30

List of Figures
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Edge Therapeutics Inc (EDGE):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Rockwool International AS:戦略・SWOT・企業財務分析
    Rockwool International AS - Strategy, SWOT and Corporate Finance Report Summary Rockwool International AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • North Energy ASA (NORTH):石油・ガス:M&Aディール及び事業提携情報
    Summary North Energy ASA (North Energy) is an upstream oil and gas company that provides exploration and development services in Norwegian Continental Shelf (NCS). The company’s services include oil and gas exploration and development, license mapping and drilling programs, and conducting geological …
  • Total SA (FP):企業の財務・戦略的SWOT分析
    Total SA (FP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • TaiMed Biologics Inc (4147):製薬・医療:M&Aディール及び事業提携情報
    Summary TaiMed Biologics Inc (TMB) is a biotechnology company that provides novel medicines for the prevention and treatment of viral infectious diseases. The company provides pipeline products such as TMB-355, TMB-607 and TMB-571, among others. It offers TMB-355 which is a proprietary humanized ant …
  • Riyad Bank:企業の戦略・SWOT・財務分析
    Riyad Bank - Strategy, SWOT and Corporate Finance Report Summary Riyad Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Nachi-Fujikoshi Corp.:企業の戦略・SWOT・財務分析
    Nachi-Fujikoshi Corp. - Strategy, SWOT and Corporate Finance Report Summary Nachi-Fujikoshi Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Oceanteam ASA (OTS):企業の財務・戦略的SWOT分析
    Oceanteam ASA (OTS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • TV Asahi Corporation (9409):企業の財務・戦略的SWOT分析
    TV Asahi Corporation (9409) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Leaf Group Ltd:企業のM&A・事業提携・投資動向
    Leaf Group Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Leaf Group Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • GfK SE:企業のM&A・事業提携・投資動向
    GfK SE - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's GfK SE Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital rais …
  • Flex Ltd.:企業の戦略・SWOT・財務分析
    Flex Ltd. - Strategy, SWOT and Corporate Finance Report Summary Flex Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Acadia Pharmaceuticals Inc (ACAD):企業の財務・戦略的SWOT分析
    Acadia Pharmaceuticals Inc (ACAD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Glacier Energy Services:石油・ガス:M&Aディール及び事業提携情報
    Summary Glacier Energy Services (Glacier) is a diversified company. The company manufactures and markets machining solutions. It provides products such as pipe cutting and bevelling equipment, coating removal equipment, riser refurbishment equipment, drilling and boring equipment, heat exchanger and …
  • Pharming Group NV (PHARM):企業の財務・戦略的SWOT分析
    Pharming Group NV (PHARM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Precision Drilling Corporation (PD):石油・ガス:M&Aディール及び事業提携情報
    Summary Precision Drilling Corp (Precision) is a provider of onshore drilling and production services to exploration and production companies in the oil and natural gas industry. It offers contract drilling, well servicing and other support services to oil and natural gas exploration and production …
  • Tristan Technologies Inc:企業の製品パイプライン分析2018
    Summary Tristan Technologies Inc (Tristan) is a medical device company that offers laboratory products. The company designs, develops and manufactures components and systems for biomagnetic measurement and clinical applications. Its products comprise biomagnetic devices, geomagnetic, cryogenic, non- …
  • National Instruments Corp (NATI):企業の財務・戦略的SWOT分析
    National Instruments Corp (NATI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Cambridge Cognition Holdings Plc (COG):医療機器:M&Aディール及び事業提携情報
    Summary Cambridge Cognition Holdings Plc (Cambridge Cognition) is a neuroscience digital health company. The company offers drug development, digital health technology and cognitive research. Its drug development service include enrich clinical trial recruitment, develop safe and effective treatment …
  • Tervita Corp:企業の戦略・SWOT・財務情報
    Tervita Corp - Strategy, SWOT and Corporate Finance Report Summary Tervita Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Polaris Industries Inc (PII):企業の財務・戦略的SWOT分析
    Polaris Industries Inc (PII) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆